ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0878588 | Organic or functional motility disorder involving the SPHINCTER OF ODDI and associated with biliary COLIC. Pathological changes are most often seen in the COMMON BILE DUCT sphincter, and less commonly the PANCREATIC DUCT sphincter. | Sphincter of Oddi dysfunction|sphincter of oddi dysfunction|sphincter oddi dysfunction|Dysfunction of sphincter of Oddi|Sphincter of Oddi Dysfunction|Dysfunction of sphincter of Oddi (disorder) | Sphincter of Oddi Dysfunction |
C0149521 | A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus. | Pancreatitis, Chronic|Chronic pancreatitis (disorder)|CP - Chronic pancreatitis|Chronic pancreatitis as main diagnosis for the pancreas|PANCREATITIS CHRONIC|pancreatitis chronic|chronic pancreatitis|Recurrent pancreatitis|Chronic pancreatitis|Chronic Pancreatitis|PANCREATITIS, CHRONIC|Chronic pancreatitis NOS|Relapsing pancreatitis|Chronic pancreatitis, NOS|recurrent pancreatitis|Chronic pancreas inflammation | Pancreatitis, Chronic |
C1550229 | null | null | Common Duct |
C0748895 | Surgical incision of a sphincter. | sphincterotomy|sphincterotomies|Sphincterotomies | Sphincterotomy |
C0005416 | A motility disorder characterized by biliary COLIC, absence of GALLSTONES, and an abnormal GALLBLADDER ejection fraction. It is caused by gallbladder dyskinesia and/or SPHINCTER OF ODDI DYSFUNCTION. | BILIARY DYSKINESIA|biliary dyskinesia|Biliary dyskinesia|Dyskinesias, Biliary|biliary dyskinesias|dyskinesia biliary|Dyskinesia, Biliary|Biliary dyskinesia (disorder)|Biliary Dyskinesias | Biliary Dyskinesia |
C0151824 | Painful sensation in the gallbladder region. | COLIC BILIARY|Biliary colic (finding)|BILIARY PAIN|colic biliary|gall bladder pain|BILIARY COLIC|bladder gall pain|PAIN BILIARY|gallbladder pain|Biliary colic symptom|Gallbladder pain|biliary colic|Gallbladder Pain|Gallbladder pain (finding)|GALL BLADDER PAIN|Biliary colic|pain gallbladder|Hepatic colic|biliary pain | Biliary Colic |
C0008328 | A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety. | Product containing cholecystokinin (medicinal product)|Cholecystikinin|Uropancreozymin|PZ - Pancreozymin|cholecystokinin|CCK-PZ|Cholecystokinin-containing product|CCK|Pancreozymin|cholecystokinin (CCK)|Cholecystokinin preparation|Human cholecystokinin-33|pancreozymin (cholecystokinin)|pancreozymin|Human CCK-33|cholecystokinins|Cholecystokinin|CCK-PZ - Cholecystokinin-pancreozymin|cck|Cholecystokinin-pancreozymin|Cholecystokinin (substance)|cholecystokinin, human | cholecystokinin |
C0036435 | Treatment of varicose veins, hemorrhoids, gastric and esophageal varices, and peptic ulcer hemorrhage by injection or infusion of chemical agents which cause localized thrombosis and eventual fibrosis and obliteration of the vessels. | Sclerosant injection|Injection of sclerosing agent|Sclerotherapies|Injection of sclerosant|Sclerotherapy|Injection of sclerosing agent, NOS|Sclerosing injection|Injection of sclerosing agent (procedure)|sclerotherapy | Sclerotherapy |
C0042300 | Structural abnormality in which a valve fails to close properly. This includes abnormalities of the valve leaflets as well as so-called functional insufficiency due to other abnormalities such as annular dilatation in the presence of morphologically normal leaflets. | regurgitation valvular|Valvular incompetence|valvular insufficiency|Incompetence of any valvular structure (finding)|valvular incompetence|Valvular regurgitation|valvular regurgitation|Valvular insufficiency|Incompetence of any valvular structure|Valvular insufficiency (morphologic abnormality) | Valvular regurgitation |
C0020223 | A direct-acting vasodilator that is used as an antihypertensive agent. | 1(2H)-Phthalazinone Hydrazone|Hydralazin|Hydralazine|Hydralazinum|6-Hydralazine|Hydrazinophthalazine|Hydrallazine|Hydrallazin|hydralazine|Product containing hydralazine (medicinal product)|Hydralazine (substance)|Hypophthalin|apressin|HYDRALAZINE|(2H)-Phthalazinone hydrazone|(1Z)-1(2H)-Phthalazinone hydrazone|1-Phthalazinylhydrazine|Idralazina|Hydralazine-containing product|Phthalazin-1-ylhydrazine|hydrALAZINE|Hydrazone 1(2H)-phthalazinone|1(2H)-Phthalazinone, hydrazone|1-Hydrazinophthalazine|Hidralazina|Apressin | hydralazine |
C0026196 | A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) | minoxidil|Minoxidil (substance)|Minossidile|MINOXIDIL|2,4-Diamino-6-piperidinopyrimidine 3-oxide|2,4-Pyrimidinediamine, 6-(1-Piperidinyl)-, 3-Oxide|6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide|Product containing minoxidil (medicinal product)|minoxidil products|2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine|Minoxidil-containing product|Minoxidilum|2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide|Minoxidil | minoxidil |
C0009014 | An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. | Clonidine|Clonidin|Clonidine (substance)|Clofenil|2-((2,6-Dichlorophenyl)imino)imidazolidine|Clonidinum|clonidine|1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-|N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine|2,6-Dichloro-N-2-imidazolidinylidenebenzenamine|cloNIDine|Klofenil|Clonidine-containing product|Product containing clonidine (medicinal product)|CLONIDINE|Clonidina | clonidine |
C0042568 | Localized or diffuse reduction in blood flow through the vertebrobasilar arterial system, which supplies the BRAIN STEM; CEREBELLUM; OCCIPITAL LOBE; medial TEMPORAL LOBE; and THALAMUS. Characteristic clinical features include SYNCOPE; lightheadedness; visual disturbances; and VERTIGO. BRAIN STEM INFARCTIONS or other BRAIN INFARCTION may be associated. | Vertebro-Basilar Ischemia|Ischemia, Vertebro-Basilar|Insufficiency, Vertebrobasilar|Vertebro-Basilar Ischemias|Vertebrobasilar Ischemias|Ischemia, Vertebrobasilar|vertebro-basilar insufficiency|Ischemias, Vertebrobasilar|Ischemias, Vertebro-Basilar|Vertebrobasilar Ischemia|Vertebro-Basilar Insufficiency|Vertebrobasilar insufficiency|Vertebrobasilar Insufficiencies|vertebral basilar insufficiency|basilar vertebral insufficiency|VERTEBRAL BASILAR INSUFFICIENCY|Vertebrobasilar artery syndrome|vertebro basilar insufficiency|Vertebro Basilar Ischemia|Insufficiencies, Vertebro-Basilar|Vertebrobasilar artery syndrome (disorder)|vertebro-basilar artery syndrome|Vertebro-Basilar Insufficiencies|Insufficiency, Vertebro-Basilar|Insufficiencies, Vertebrobasilar|vertebrobasilar ischemia|Vertebro Basilar Insufficiency|Vertebrobasilar arterial insufficiency|VERTEBRAL BASILAR ARTERY INSUFFICIENCY|vertebrobasilar artery syndrome|vertebrobasilar insufficiency | Vertebrobasilar Insufficiency |
C0009780 | Tissue that supports and binds other tissues. It consists of CONNECTIVE TISSUE CELLS embedded in a large amount of EXTRACELLULAR MATRIX. | Connective tissue (substance)|Portion of connective tissue|Textus connectivus|Connective tissue|Connective tissue structure (body structure)|Connective tissues|Connective tissue structure|Tissues, Connective|Connective tissue, NOS|Connective Tissue|connective tissues|Tissue, Connective|connective tissue|CONNECTIVE TISSUE|Connective Tissues | Connective Tissue |
C0013720 | A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability. | cutis elastica|EDS|Dystrophia mesodermalis congenita|CUTIS HYPERELASTICA|ehlers-danlos syndrome|Cutis Elastica|Ehler Danlos Syndrome|cutis hyperelastica|Cutis hyperelastica dermatorrhexis|Syndrome, Ehlers-Danlos|Cutis hyperelastica|Hereditary collagen dysplasia|Ehlers Danlos Disease|elastic skin|Disease, Ehlers Danlos|Fibrodysplasia elastica generalisata|Ehlers-Danlos syndrome|EHLERS-DANLOS SYNDROME|Ehlers Danlos Syndrome|Disease, Ehlers-Danlos|India rubber skin|Ehlers-Danlos syndrome, NOS|Ehlers-Danlos syndrome (disorder)|danlos ehlers syndrome|Cutis elastica|Meekeren-Ehlers-Danlos syndrome|danlos disease|Ehlers-Danlos Disease|Ehlers-Danlos Syndrome|skin elastic|ehlers danlos syndrome|ehler danlos syndrome|Ehlers Danlos syndrome|Danlos disease|Danlos Disease, Ehlers|eds ehlers danlos syndrome|ehlers danlos syndromes | Ehlers-Danlos Syndrome |
C0423153 | Tearing; excessive shedding of tears. | tearing|LACRIMATION|tear production|lacrimation|Lacrimation|Tearing | Lacrimation |
C0013720 | A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability. | cutis elastica|EDS|Dystrophia mesodermalis congenita|CUTIS HYPERELASTICA|ehlers-danlos syndrome|Cutis Elastica|Ehler Danlos Syndrome|cutis hyperelastica|Cutis hyperelastica dermatorrhexis|Syndrome, Ehlers-Danlos|Cutis hyperelastica|Hereditary collagen dysplasia|Ehlers Danlos Disease|elastic skin|Disease, Ehlers Danlos|Fibrodysplasia elastica generalisata|Ehlers-Danlos syndrome|EHLERS-DANLOS SYNDROME|Ehlers Danlos Syndrome|Disease, Ehlers-Danlos|India rubber skin|Ehlers-Danlos syndrome, NOS|Ehlers-Danlos syndrome (disorder)|danlos ehlers syndrome|Cutis elastica|Meekeren-Ehlers-Danlos syndrome|danlos disease|Ehlers-Danlos Disease|Ehlers-Danlos Syndrome|skin elastic|ehlers danlos syndrome|ehler danlos syndrome|Ehlers Danlos syndrome|Danlos disease|Danlos Disease, Ehlers|eds ehlers danlos syndrome|ehlers danlos syndromes | Ehlers-Danlos Syndrome |
C0001363 | Ischemia of the intestine that is rapid in onset. | acute ischemia mesenteric|Acute intestinal vascular insufficiency|Acute vascular insufficiency of intestine, NOS|Acute intestinal ischaemic syndrome, NOS|MESENTERIC VASCULAR INSUFFICIENCY, ACUTE|Acute vascular insufficiency of intestine|Acute vascular insufficiency of intestine (disorder)|Acute intestinal ischaemia|Acute intestinal ischemic syndrome, NOS|Acute intestinal ischaemic syndrome|acute mesenteric ischemia|Acute intestinal ischemic syndrome|Acute intestinal ischemia|Acute mesenteric ischemia|acute intestinal ischaemia|AMI - Acute mesenteric ischaemia|acute mesenteric ischaemia|Acute Intestinal Ischemia|Acute mesenteric ischaemia|AMI - Acute mesenteric ischemia|ACUTE MESENTERIC ISCHEMIA | Acute vascular insufficiency of intestine (disorder) |
C0042402 | Drugs used to cause dilation of the blood vessels. | Medicinal product acting as vasodilator (product)|vasodilator agents|Drugs, Vasodilator|Agents, Vasodilator|Vasodilator (substance)|drugs vasodilators|Vasodilator Drugs|Vasodilating agent, NOS|VASODILATING AGENTS|Vasorelaxants|vasodilators|Vasodilator Agents|Vasodilator agent|vasodilator drugs|Vasodilator|Vasodilating Agent|vasodilator|substances vasodilator|Vasodilator drug|Vasodilators | Vasodilator Agents |
C0004455 | The continuation of the subclavian artery; it distributes over the upper limb, axilla, chest and shoulder. | Axillary Artery|Artery, Axillary|Axillary part of subclavian artery|Axillary artery|AXILLARY ARTERIES|Arteries, Axillary|Axillary Arteries|Arteria axillaris|arteries axillary|Structure of axillary artery (body structure)|Axillary artery, NOS|axillary artery|Axillary part of trunk of subclavian artery|Structure of axillary artery|AXILLARY ARTERY|axillary arteries | Structure of axillary artery |
C0032743 | An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower. | imaging pet|POSITRON EMISSION TOMOGRAPHY|Positron Emission Tomography Scan|PET scan|Positron emission tomographic imaging - action (qualifier value)|Positron emission tomography (procedure)|Positron emission tomographic imaging|PET Scans|positron emission tomography scan|PETT|pet scans|Scans, PET|Medical Imaging, Positron Emission Tomography|positron emission tomography|Scan, PET|PET SCAN|PET|pet|PET imaging|PET Scan|pet imaging|Positron emission tomography, NOS|Positron Emission Tomography|Positron emission tomography (PET)|Positron-Emission Tomography|pet scan|proton magnetic resonance spectroscopic imaging|Tomography, Positron-Emission|Positron emission tomography|PET - Positron emission tomography|positron-emission tomography|positron-emission tomography (PET)|Positron emission tomographic imaging - action|PET scan, NOS|Tomography, Positron Emission | Positron-Emission Tomography |
C0243032 | Non-invasive method of vascular imaging and determination of internal anatomy without injection of contrast media or radiation exposure. The technique is used especially in CEREBRAL ANGIOGRAPHY as well as for studies of other vascular structures. | MRA|Vascular magnetic resonance imaging|Magnetic resonance imaging (MRI) of vessels|Magnetic resonance angiography|Magnetic resonance imaging of vessels|Magnetic Resonance Angiography|Magnetic resonance angiography, NOS|Magnetic Resonance Angiographies|Angiography, MRI|MRI Angiographies|Magnetic resonance imaging of vessels (procedure)|magnetic resonance angiography|Angiographies, MRI|magnetic resonance angiography (MRA)|Vascular MRI|Angiographies, Magnetic Resonance|Angiography, Magnetic Resonance|MRI Angiography|mra | Magnetic Resonance Angiography |
C0017725 | A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. | Dextrosa|d-Glucose preparation|Dextrose, Unspecified Form|D-glucose|D-Glucose|Dextrose, unspecified form|Dextrose preparation|Glucose (substance)|Glucose|glucose|endocrine glucose|D-glucose preparation|dextrose|glucose preparations|Glucose-containing product|Dextrose, unspecified|D Glucose|Glucose preparation|Glucose, NOS|DEXTROSE|glucoses|6-(hydroxymethyl)oxane-2,3,4,5-tetrol|D(+)-Glucose|DEXTROSE, UNSPECIFIED FORM|dextrose, unspecified form|GLUCOSE|Dextrose, Unspecified form|Product containing glucose (medicinal product)|d-glucose|Glucosa|D-glucopyranose monohydrate preparation|Grape sugar|Dextrose | glucose |
C0014804 | A peripheral arterial disease that is characterized by the triad of ERYTHEMA, burning PAIN, and increased SKIN TEMPERATURE of the extremities (or red, painful extremities). Erythromelalgia may be classified as primary or idiopathic, familial or non-familial. Secondary erythromelalgia is associated with other diseases, the most common being MYELOPROLIFERATIVE DISORDERS. | erythromelalgia|gerhardt disease|Erythermalgia|GERHARDT DISEASE|Erythromelalgia|Erythromelalgia (disorder)|ERYTHROMELALGIA|erythermalgia|Erythermalgias|Erythralgia|Weir Mitchell's disease|ERYTHERMALGIA|weir mitchell's disease|Erythromelalgias|Weir-Mitchell disease|MITCHELL DISEASE|WEIR MITCHELL SYNDROME|mitchell disease | Erythromelalgia |
C0018188 | A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents. | GRANULOMAS|Granulomas|Granuloma|Granuloma, NOS|granulomatous lesion|granuloma|granulomas|Granulomatous Lesion|Histiocytic granuloma|Epitheloid granuloma|GRANULOMATOUS LESION|Epithelioid granuloma|GRANULOMA|granulomatous lesions|epithelioid granulomas|Granuloma (morphologic abnormality) | Granuloma |
C0340630 | null | Aneurysm, Thoracoabdominal Aortic|Thoracoabdominal Aortic Aneurysms|Thoracoabdominal Aortic Aneurysm|Thoracoabdominal aortic aneurysm (disorder)|Aneurysms, Thoracoabdominal Aortic|Thoracoabdominal aortic aneurysm|Aortic Aneurysms, Thoracoabdominal | Aortic Aneurysm, Thoracoabdominal |
C1182459 | null | null | Differentiated muscle cell |
C0597220 | any substance or agent which suppresses, prevents or opposes the actions of phospholipases. | phospholipase inhibitor | phospholipase inhibitor |
C0051761 | The deoxycholate salt of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane. This results in depolarization of the cell membrane, alterations in cell membrane permeability, leakage of important intracellular components, and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells. | D-AmB cpd|amphotericin B-deoxycholate|Amphotericin B-deoxycholate|amphotericin B deoxycholate|amphotericin B - deoxycholate|HAmB-DOC|Amphotericin B Deoxycholate | amphotericin B, deoxycholate drug combination |
C1514555 | Any substance that inhibits protein kinase c (PKC), a serine/threonine protein kinase that catalyzes certain cell protein phosphorylation reactions involved in inflammation, mitogenesis, and cell differentiation. | null | Protein Kinase C Inhibitor |
C0376519 | A noninvasive technique that uses the differential absorption properties of hemoglobin and myoglobin to evaluate tissue oxygenation and indirectly can measure regional hemodynamics and blood flow. Near-infrared light (NIR) can propagate through tissues and at particular wavelengths is differentially absorbed by oxygenated vs. deoxygenated forms of hemoglobin and myoglobin. Illumination of intact tissue with NIR allows qualitative assessment of changes in the tissue concentration of these molecules. The analysis is also used to determine body composition. | Near-Infrared Spectroscopy|Spectrometry, Near Infrared|NIR Spectroscopy|Spectrometry, Near-Infrared|Spectroscopy, NIR|Near-Infrared Spectrometries|near-infrared spectroscopy|Near-Infrared Spectroscopies|Spectroscopy, Near Infrared|NIRS - Near infrared spectroscopy|Near infrared spectroscopy|NIR Spectroscopies|NIR spectroscopy|Spectroscopies, Near-Infrared|Near-infrared spectroscopy|near infrared spectrometry|near infrared spectroscopy|Near-infrared spectroscopy (procedure)|Spectrometries, Near-Infrared|Near-Infrared Spectrometry|Spectroscopies, NIR | Spectroscopy, Near-Infrared |
C0032821 | An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE. | Kalium|Potasio|Potassium|Potassium, metal|POTASSIUM|Product containing potassium (medicinal product)|K element|Potassium-containing product|Potassium metal|Potassium, elemental|Potassium (substance)|kalium|Potassium (NOS)|potassium(1+)|K - Potassium|K|potassium|Potassium, NOS | potassium |
C0039705 | An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction. | Tetradotoxin|ttx|Puffer fish toxin|Tetrodotoxin|puffer fish toxin|5,9:7,10a-Dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, Octahydro-12-(hydroxymethyl)-2-imino-|Tetrodotoxin (substance)|Babylonia Japonica Toxin 1|TETRODOTOXIN|tetradotoxin|Tarichatoxin|Toxin, Fugu|Fugu Toxin|tetrodotoxin|tarichatoxin|TTX|tetrodotoxins | Tetrodotoxin |
C0971866 | null | null | Myofibrillogenesis |
C0030049 | A semisynthetic derivative of CODEINE. | Oxycone|oxycodone|Dihydroxycodeinone|Oxycodone|Oxycodone SR|Oxycodone (substance)|Dihydrone|14-Hydroxydihydrocodeinone|4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one|Dihydrohydroxycodeinone|(-)-14-Hydroxydihydrocodeinone|oxyCODONE|Oxycodonum|Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-|Product containing oxycodone (medicinal product)|4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one|OXYCODONE|Oxycodeinon|dihydrohydroxycodeinone|Oxicodona|Oxycodone-containing product|14-hydroxydihydrocodeinone|Dihydro-14-hydroxycodeinone|4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one | oxycodone |
C0026549 | The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. | morphines|Morphia|(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol|Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-|Morphine (substance)|(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol|(-)-morphine|Morfina|Morphine-containing product|(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol|Morphinum|morphine product|(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol|Morphin|morphine|(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol|Morphium|(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol|Morphine|MORPH|MORPHINE|Product containing morphine (medicinal product) | morphine |
C0053608 | null | BNI ligand | binaltorphimine |
C0066908 | A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine. | Opioid Receptor, mu|Receptors, mu Opioid|mu-opioid receptors|Receptor, mu Opioid|Opioid Receptors, mu|mu Opioid Receptors|Receptors, mu|Receptor, mu|mu receptor|mu Opioid Receptor|mu Receptor|mu Receptors|Receptors, Opioid, mu | Receptors, Opioid, mu |
C0037567 | The sodium salt form of valproic acid with anti-epileptic activity. Valproate sodium is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, valproate sodium increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproate sodium may also affect potassium channels, thereby creating a direct membrane-stabilizing effect. | Valproate sodium|Valproate, sodium|Sodium valproate|Sodium alpha-propylvalerate|Sodium dipropylacetate|valproate sodium|DPA sodium|sodium valproate|2-Propylpentanoic Acid Sodium Salt|VALPROATE SODIUM|Valproate sodium (substance)|Sodium Valproate|Valproate Sodium | sodium valproate |
C0006949 | A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. | 5-Carbamoyl-5H-dibenz(b,f)azepine|5-Carbamyl-5H-dibenzo(b,f)azepine|Carbamazepen|CBZ|Carbamazépine|CARBAMAZEPINE|Carbamazepina|Carbamazepine (substance)|5H-Dibenz(b,f)azepine-5-carboxamide|Carbamazepinum|carBAMazepine|5-carbamoyl-5H-dibenz[b,f]azepine|5-Carbamoyl-5H-dibenzo(b,f)azepine|carbamazepine|Carbamazepine|Carbamazepine-containing product|Product containing carbamazepine (medicinal product)|carbamazepines|Carbamazepin | carbamazepine |
C1550315 | null | null | Synovial |
C0045376 | null | 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline|NBQX|6-nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione | 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline |
C0036628 | A saclike, glandular diverticulum on each ductus deferens in male vertebrates. It is united with the excretory duct and serves for temporary storage of semen. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) | Seminal vesicle|Seminal Vesicle|GLAND, SEMINAL VESICLE|Glandula vesiculosa|SEMINAL VESICLE|Seminal Sacs|Vesicula seminalis|Seminal vesicular|glands seminal|Seminal gland|Seminal vesiculo-|vesicula seminalis|Seminal vesicle structure (body structure)|Seminal vesicles|SEMINAL VESICLES|Seminal vesicle structure|Vesicle, Seminal|Glandula seminalis|Seminal Vesicles|Seminal vesicle, NOS|Vesicles, Seminal|seminal vesicles|seminal vesicle | Seminal Vesicles |
C1268455 | null | Ultrastructural feature (cell structure) | Ultrastructural feature |
C0029219 | Specific particles of membrane-bound organized living substances present in eukaryotic cells, such as the MITOCHONDRIA; the GOLGI APPARATUS; ENDOPLASMIC RETICULUM; LYSOSOMES; PLASTIDS; and VACUOLES. | Organelle (cell structure)|cell organelles|organelles|Cell organelles|Organelle structure|Organelle|organelle|Organelles|cell organelle | Organelles |
C0886515 | Vesicles derived from the GOLGI APPARATUS containing material to be released at the cell surface. | Secretory granule, NOS|Secretory granule|secretory vesicle|Granule, Secretory|Granules, Secretory|Secretory Granule|Secretory Granules|Vesicle, Secretory|Secretory Vesicle|Secretory Vesicles|Vesicles, Secretory|Secretory granule (cell structure) | Secretory Vesicles |
C0162326 | The sequence of nucleotide residues along a DNA chain. | Sequence|Sequences|dna sequence|DNA Sequence|dna sequences|Sequence, DNA|DNA sequencing|DNA sequence|DNA Sequences|Sequences, DNA | DNA Sequence |
C0042974 | Hereditary or acquired coagulation disorder characterized by a qualitative or quantitative deficiency of the von Willebrand factor. The latter plays an important role in platelet adhesion. Signs and symptoms include bruises, nose bleeding, gum bleeding following a dental procedure, heavy menstrual bleeding, and gastrointestinal bleeding. | Vascular Pseudohemophilias|Disorder, Von Willebrand|VON WILLEBRAND DISEASE|VON WILLEBRANDS DISEASE|von willebrands disease|pseudohemophilia|PSEUDOHEMOPHILIA|von Willebrand's Diseases|Angiohemophilia, A|von willebrand disease|Factor VIII deficiency with vascular defect|von Willebrand Diseases|Angiohemophilias|Angiohaemophilia|Pseudohemophilias, Vascular|von Willebrand disorder (disorder)|Von Willebrand Disorder|von willebrand's disease|Pseudohemophilia|von Willebrand's Disease|von Willebrand Disorder|WILLEBRAND-JUERGENS DISEASE|disease von willebrand|von Willebrand disease|Vascular pseudohemophilia|Vascular Hemophilias|VON WILLEBRAND'S DISEASE|Angiohemophilia|HEMOPHILIA, VASCULAR|Von Willebrand's Factor Deficiency|von Willebrand's disease|von Willebrand's-Jurgens' disease|Hemophilia, Vascular|VASCULAR HEMOPHILIA|Pseudohemophilia, Vascular|von willebrand disorder|vascular hemophilia|Vascular haemophilia|ANGIOHEMOPHILIA|Vascular Pseudohemophilia|Pseudohemophilia type B|vWD - von Willebrand's disease|Vascular hemophilia|von Willebrand Disease|angiohemophilia|Vascular Hemophilia|Angiohemophilia, B|von Willebrand disorder|diseases von willebrand's|von Willebrand disease, NOS|Constitutional thrombopathy|Pseudohaemophilia type B|von Willebrand-Jurgens disease|disease von willebrands|Von Willebrand disease|Von Willebrand's disease | von Willebrand Disease |
C0007202 | Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. | Cardiopulmonary perfusion|Heart-Lung Bypass|Bypass, Heart-Lung|Artificial heart and lung|Cardiopulmonary Bypass|Cardiopulmonary bypass operation|Cardiopulmonary Bypasses|Cardiopulmonary bypass operation (procedure)|Bypass, Cardiopulmonary|heart/lung bypass|Heart-Lung Bypasses|Heart lung bypass|Cardiopulmonary bypass|Heart Lung Bypass|heart-lung bypass|Bypasses, Heart-Lung|cardiopulmonary bypass|heart lung bypass|CPB - Cardiopulmonary bypass|heart bypass|Bypasses, Cardiopulmonary | Cardiopulmonary Bypass |
C0184047 | null | traps|trap | Trap medical device |
C0015354 | Diversion of blood flow through a circuit located outside the body but continuous with the bodily circulation. | Circulation, Extracorporeal|circulation extracorporeal|extracorporeal circulation|Extracorporeal circulation procedure (procedure)|Extracorporeal circulation procedure|Extracorporeal Circulations|Circulations, Extracorporeal | Extracorporeal Circulation |
C0444263 | null | Plasma specimen (specimen)|Plasma sample | Plasma specimen |
C0947647 | Move, treat, or operate with the hands or by mechanical means, especially in a skillful manner. | manipulation|Manipulation procedure|Manipulative|Manipulation|Manipulative procedure|Manipulate|Manipulation (procedure)|Manipulation - action|Manipulation - action (qualifier value)|manipulation procedure | Manipulation procedure |
C0032961 | The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. | PREGNANCY|Pregnancy, NOS|Pregnancy, function|Pregnancy, function (observable entity)|Gestation|mammalian gestation|gestation|Pregnancy|pregnancy|pregnancies|Gestation, NOS|female pregnancy|Pregnancies | Pregnancy |
C0026559 | The development of anatomical structures to create the form of a single- or multi-cell organism. Morphogenesis provides form changes of a part, parts, or the whole organism. | Morphogenesis|anatomical structure arrangement|anatomical structure organization|organization of an anatomical structure|structural organization|Morphogenesis, function (observable entity)|morphogenesis|Morphogenesis, function|anatomical structure morphogenesis|anatomical structure structural organization | Morphogenesis |
C0017421 | The female reproductive organs. The external organs include the VULVA; BARTHOLIN'S GLANDS; and CLITORIS. The internal organs include the VAGINA; UTERUS; OVARY; and FALLOPIAN TUBES. | Female genital organ structure (body structure)|Female genital organs, NOS|Female genital system|Genital Organs, Female|Female genital structure|Female genital|Genital, Female|Female genital structure (body structure)|female genital organs|Female Genital Organ|FEMALE GENITAL SYSTEM|Female genital organ structure|female genitalia|Female Genital Organs|Female genital organs|female genitals|Female genital system, NOS|female genital system|Female Genitals|female genital tract|Genital Organ, Female|Female genital (qualifier value)|Female Genitalia|genitals (female)|Generative organs, Female|female genital organ|female genital|Female genital organ|Genitalia, Female|Genitals, Female|FEMALE GENITALIA|FEMALE GENITAL SYSTEM: GENERAL TERMS|Female Genital | Female genitalia |
C0950105 | A genus of the family RETROVIRIDAE consisting of viruses with either type B or type D morphology. This includes a few exogenous, vertically transmitted and endogenous viruses of mice (type B) and some primate and sheep viruses (type D). MAMMARY TUMOR VIRUS, MOUSE is the type species. | Type B Mammalian Retrovirus|Retroviruses, Type B, Mammalian|Type B Virus|Betaretrovirus|Genus Betaretrovirus|Betaretroviruses|betaretrovirus|Genus Betaretrovirus (organism) | Betaretrovirus |
C1159455 | The formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane. Syncytia are normally derived from single cells that fuse or fail to complete cell division. [ISBN:0198506732] | null | syncytium formation |
C0032058 | The development of the PLACENTA, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and FETUS. The process begins at FERTILIZATION, through the development of CYTOTROPHOBLASTS and SYNCYTIOTROPHOBLASTS, the formation of CHORIONIC VILLI, to the progressive increase in BLOOD VESSELS to support the growing fetus. | Placentation|Placental Development|placentation|Placentation, function|placental development|placenta development|Placentation, function (observable entity) | Placentation |
C0042149 | The hollow thick-walled muscular organ in the female PELVIS. It consists of the fundus which is the site of EMBRYO IMPLANTATION and FETAL DEVELOPMENT. Beyond the isthmus at the perineal end of fundus, is CERVIX UTERI (the neck) opening into VAGINA. Beyond the isthmi at the upper abdominal end of fundus, are the FALLOPIAN TUBES. | Uteri|uterine|Uterus, NOS|Womb structure|Wombs|Uterine structure (body structure)|uterus|Womb|Uterus|Genital System, Female, Uterus|Utero|Utero-|Uterine structure|womb|wombs|Uterine|UTERUS | Uterus |
C1332322 | A protein that promotes the initiation, progress, or rate of apoptosis. | Inducer of Apoptosis | Apoptosis Promoter |
C1332322 | A protein that promotes the initiation, progress, or rate of apoptosis. | Inducer of Apoptosis | Apoptosis Promoter |
C0206530 | Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not. | Mutation, Germ Line|germline mutation|Germ-Line Mutations|Mutations, Germline|Mutations, Germ-Line|Germline Mutation|Hereditary Mutation|Germ-Line Mutation|Germline Mutation Abnormality|Germ Line Mutation|Mutation, Germ-Line|Germline Mutations|hereditary mutation|germ-line mutation|germline mutations|Mutation, Germline | Germ-Line Mutation |
C0544886 | An alteration in DNA that occurs after conception. Somatic mutations can occur in any of the cells of the body except the germ cells (sperm and egg) and therefore are not passed on to children. These alterations can (but do not always) cause cancer or other diseases. | Somatic mutation (finding)|Somatic Mutation|Somatic Mutation Abnormality|Somatic mutation|Mutation, somatic|somatic mutations|somatic mutation | Somatic mutation |
C0023449 | Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia. | ALL - Acute lymphoblastic leukaemia|Acute lymphoid leukemia, disease|Acute Lymphoblastic Leukemia (ALL)|lymphocytic leukemia acute|Lymphoid leukemia, acute|Acute lymphoid leukemia|Lymphoblastic Leukemia|acute lymphatic leukemia|Acute lymphocytic leukaemia|acute lymphocytic leukemia (ALL)|Acute lymphoid leukemia, disease (disorder)|ALL|acute lymphocytic leukemia|Lymphoblastic leukemia|Acute lymphoid leukaemia, disease|acute lymphatic leukaemia|Acute lymphoid leukaemia|ALL - Acute lymphoblastic leukemia|acute leukemia lymphoid|Acute lymphoblastic leukemia-lymphoma|leukemia - acute lymphoblastic|Acute Lymphoblastic Leukemia|acute lymphoblastic leukaemia|Precursor Lymphoblasic Leukemia|Acute lymphoblastic leukaemia|Leukemia, Acute Lymphocytic|LEUKEMIA ACUTE LYMPHOBLASTIC|leukemia, acute lymphocytic|ACUTE LYMPHOCYTIC LEUKEMIA|Acute Lymphocytic Leukemias|Acute Lymphoid Leukemia|ALL - Acute Lymphocytic Leukemia|LEUKEMIA LYMPHOBLASTIC ACUTE|Acute Lymphocytic Leukemia|acute lymphocytic leukaemia|Acute Lymphocytic Leukaemia|acute leukemia lymphoblastic|ACUTE LYMPHOBLASTIC LEUKEMIA|acute lymphoblastic leukemia|acute lymphoblastic leukemias|lymphoblastic leukaemia|leukemia acute lymphoblastic|Lymphoblastic leukaemia|leukemia lymphoblastic|Acute Lymphogenous Leukemia|LEUKEMIA, LYMPHOCYTIC, ACUTE|Acute lymphoblastic leukemia, NOS|Precursor Cell Lymphoblastic Leukemia|Acute lymphatic leukemia|acute leukemia lymphocytic|LEUKEMIA, LYMPHOBLASTIC, ACUTE|Acute lymphoblastic leukemia|acute lymphoid leukemia|acute lymphogenous leukemia|Acute lymphoblastic leukaemia-lymphoma|lymphoblastic leukemia|Precursor Lymphoblastic Leukemia|Acute lymphocytic leukemia|acute leukaemia lymphoblastic|Acute lymphatic leukaemia|LEUKEMIA, LYMPHOBLASTIC, MALIGNANT | Acute lymphocytic leukemia |
C1335781 | null | null | Rhabdomyosarcomatous Differentiation |
C1335781 | null | null | Rhabdomyosarcomatous Differentiation |
C0796357 | Germline genetic testing method targeted to detect a specific mutation (such as a deleterious MSH2 mutation previously identified in a family), panel of mutations (such as the 3 BRCA mutations comprising the founder mutation panel for individuals of Ashkenazi Jewish ancestry) or type of mutation (such as a large deletions or insertions in the BRCA1 gene). This type of testing is distinct from complete gene sequencing or mutation scanning. The latter are designed to detect most mutations in the region being tested. Current usage also applies this term to any genetic test. | Mutation Analysis|GENVAR|mutation analysis|Genetic Variation Analysis|Genetic Variation | Genetic Variation Analysis |
C1413815 | This gene is involved in osteoclastic bone resorption. | CTSK Gene|CATHEPSIN K|CTSK gene|cathepsin K|PKND|CTSK|Cathepsin K Gene | CTSK gene |
C1413815 | This gene is involved in osteoclastic bone resorption. | CTSK Gene|CATHEPSIN K|CTSK gene|cathepsin K|PKND|CTSK|Cathepsin K Gene | CTSK gene |
C0023480 | A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood. | Chronic myelomonocytic leukemia (morphologic abnormality)|Leukemias, Chronic Myelomonocytic|CMML|cmml|chronic myelomonocytic leukaemia|LEUKEMIA, CHRONIC MYELOMONOCYTIC|Chronic myelomonocytic leukaemia|Myelomonocytic Leukemia, Chronic|Chronic Myelomonocytic Leukemia|Leukemia, Myelomonocytic, Chronic|Leukemia, Chronic Myelomonocytic|Chronic Myelomonocytic Leukemia (CMML)|myelomonocytic leukemia, chronic|Myelomonocytic Leukemias, Chronic|Chronic myelomonocytic leukemia (disorder)|Chronic Myelomonocytic Leukemias|Chronic myelomonocytic leukemia|chronic myelomonocytic leukemia | Leukemia, Myelomonocytic, Chronic |
C0024262 | Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. | Transformation, Lymphocyte|blastogenesis|blasts transformation|lymphocyte activation|Lymphocyte Activation|Blastogenesis|Lymphoblast Transformation|Lymphocyte Activation Process|Transformation, Blast|Lymphocyte transformation|Blast Transformation|activation lymphocyte|lymphocyte transformation|Activation, Lymphocyte|Lymphocyte Stimulation|Transformation, Lymphoblast|Lymphocyte Transformation|Stimulation, Lymphocyte|blast transformation | Lymphocyte Activation |
C0002893 | A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy. | Aregenerative Anemia|refractory anemia|Refractory anaemia, NOS|Refractory anemia|Refractory anemia, NOS|refractory anemias|REFRACTORY ANEMIA|Anemias, Refractory|Refractory Anemias|Anemia, Refractory|ANEMIA REFRACTORY|refractory anaemia|ANEMIA, REFRACTORY|Refractory anemia (RA)|Refractory Anemia|Refractory anemia (morphologic abnormality)|anemia refractory|RA|Refractory anaemia | Refractory anemias |
C0205039 | Having to do with the bronchi, which are the larger air passages of the lungs, including those that lead from the trachea (windpipe) to the lungs and those within the lungs. | Bronchial|bronchial|bronchio|Bronchio-|Bronchial (qualifier value) | Bronchial |
C0024314 | Disorders characterized by proliferation of lymphoid tissue, general or unspecified. | diseases lymphoproliferative|lymphoproliferative disease|Lymphoproliferative disorders|lymphoproliferative disorder nos|duncan's syndrome|Lymphoproliferative disease|Lymphoproliferative disease, no ICD-O subtype|disorders lymphoproliferative|Lymphoproliferative disease, NOS|Lymphoproliferative disease, no International Classification of Diseases for Oncology subtype|lymphoproliferative disorders|Lymphoproliferative disorder (disorder)|Lymphoproliferative Disorders|lymphoproliferative disorder|Lymphoproliferative disorder|Lymphoproliferative disease, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Lymphoproliferative disorder (morphologic abnormality)|Duncan's syndrome|duncans syndrome|duncan syndrome|Disorder, Lymphoproliferative|Lymphoproliferative Disorder|Disorders, Lymphoproliferative | Lymphoproliferative Disorders |
C0002199 | One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. | Interferon alpha|Product containing interferon alfa (medicinal product)|HuIFN-alpha-Le|Interferon Alfa|leukocyte interferon|Interferon, Lymphoblastoid|Interferon alfa (substance)|Interferon alfa-containing product|alpha Interferon|Interferon, alpha|Lymphoblastoid Interferon|interferon-alpha|IFN-α|IFNa|alpha-Interferon|Interferon alfa|alpha interferon|Interferon, Lymphoblast|Leukocyte Interferon|alpha interferons|alpha-interferon|Lymphoblast Interferon|Natural alpha interferon|Alpha interferon|Interferon-alpha|interferon alfa|interferon alpha|interferon alfa natural|Interferon, Leukocyte | Interferon-alpha |
C1171362 | The biosynthesis of new (often sets of distinct, functionally related) protein products, usually involving new mRNA transcripts, typically in response to an activating stimulus. | protein expression|Protein Expression|expression protein|Expressed | protein expression |
C0053448 | null | beta-hexachloran|(+--)-beta-hexachlorocyclohexane|beta-benzene hexachloride|beta-Lindane|beta-HCH|beta-hexachlorobenzene|(1 alpha,2 beta,3 alpha,4 beta,5 alpha,6 beta)-1,2,3,4,5,6-hexachlorocyclohexane|beta-1,2,3,4,5,6-hexachlorocyclohexane|cyclohexane, 1,2,3,4,5,6-hexachloro-, beta-|beta-666 | beta-hexachlorocyclohexane |
C1550099 | Material that has settled out of solution. | Sediment | Sediment |
C0013328 | An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide. | Chlorpyrifos|Chlorpyrifos (substance)|Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester|chlorpyrifos | Chlorpyrifos |
C0043791 | A synthetic oil with anti-obesity activity. The enzymatically synthesized isoform, 1,3-isoform diacylglycerol, is suggested to decrease formation of chylomicrons as well as shunting them directly to the liver through the portal vein where they are oxidized. Increased beta-oxidation may enhance body weight loss, suppress body fat accumulation and lower serum triacylglycerol levels through increasing satiety. | Diglyceride|dag|dags|1, 2-Diacylglycerol|Diacylglycerol|DAG|1, 2-diacylglycerol|diacylglycerol|1, 2-diacylglycerol (substance)|DIGLYCERIDE|diglyceride|1,2-diacylglycerol | 1,2-diacylglycerol |
C0021547 | An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction. | Chiro-Inositol|L-myo-Inositol|inositol|myo-Inositol|Inositol|myoinositol|chiro-inositol|cis-1,2,3,5-trans-4,6-cyclohexanehexol|Cyclohexanehexol|Inositol-containing product|meso-Inositol|Anti-alopecia factor|INOSITOL|Chiro Inositol|Inose|Myoinositol|cis-1,2,3,5-trans-4,6-Cyclohexanehexol|Mesoinositol|cyclohexanehexol|Inositol (substance)|myo-inositol|Myo-inositol|Product containing inositol (medicinal product)|1,2,3,5/4,6-cyclohexanehexol | inositol |
C0043791 | A synthetic oil with anti-obesity activity. The enzymatically synthesized isoform, 1,3-isoform diacylglycerol, is suggested to decrease formation of chylomicrons as well as shunting them directly to the liver through the portal vein where they are oxidized. Increased beta-oxidation may enhance body weight loss, suppress body fat accumulation and lower serum triacylglycerol levels through increasing satiety. | Diglyceride|dag|dags|1, 2-Diacylglycerol|Diacylglycerol|DAG|1, 2-diacylglycerol|diacylglycerol|1, 2-diacylglycerol (substance)|DIGLYCERIDE|diglyceride|1,2-diacylglycerol | 1,2-diacylglycerol |
C1516828 | null | Embryonic Tissue - MEF (MMHCC) | Mouse Embryonic Fibroblast |
C0475358 | A tumor sample, or entire tumor that is removed for microscopic examination. | samples tissue tumor|Tumor tissue|Tumor Sample|tissue tumors|TUMOR TISSUE|tumor tissue|tissue tumor|Tumor Tissue|tissue tumours|Tumour tissue sample|Tumor tissue sample (specimen)|Tumour tissue|tissues tumor | Tumor tissue sample |
C0152054 | Placing of the hands of the healer upon the person to be cured with the intent of spiritual energetic healing. | Therapeutic Touch|Touch (regime/therapy)|Touch, Therapeutic|Healing Touch|therapeutic touch|Therapeutic touch|Touch|Therapeutic touch (regime/therapy)|healing touch|touch healing | Therapeutic tactile stimulation |
C0034629 | A naturally radioactive element with atomic symbol Rn, and atomic number 86. It is a member of the noble gas family found in soil, and is released during the decay of RADIUM. | radon|Radon (substance)|RADON|Radon|Rn element|Radon, NOS|Rn | Radon |
C1166698 | A type of chromosome in a polyploid cell, formed when multiple copies of homologous chromosomes are aligned side by side to give a giant chromosome in which distinct chromosome bands are readily visible. [ISBN:0198506732] | polytene chromosome|Polytene Chromosome|Chromosome, Polytene|Chromosomes, Polytene | Polytene Chromosomes |
C0009968 | A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55. | copper supplement|Copper|Cu|Copper, NOS|cuprum|cobre|Kupfer|Copper-containing product|copper in a drug form|Copper (substance)|cu|Copper-63|copper|copper (cu)|Copper 63|COPPER|Cu element|Product containing copper (medicinal product)|coppers|Cu - Copper|cuivre | copper |
C0018738 | Encouraging consumer behaviors most likely to optimize health potentials (physical and psychosocial) through health information, preventive programs, and access to medical care. | Promotion of Health|Health promotion|Health stimulation/nurturance treatments and procedures|promotion of health|Promotion, Health|Health promotion (regime/therapy)|health promotion|Promotions, Health|health promotions|Health Promotions|Health Promotion | Health Promotion |
C1446377 | null | Mental health problem (finding) | Mental health problem |
C0056476 | null | cremophore EL | cremophor EL |
C0549255 | The addition of energy to a system, thereby transferring it from its ground state to an excited state. | excitation|Excite|Excited|Excitation | Excitation |
C0055863 | A naturally-occurring rock or soil constituent characterized by particles with a diameter of less than 0.005 mm. It is composed primarily of hydrous aluminum silicates, trace amounts of metal OXIDES, and organic matter. | clays|Clays|Clay|clay | clay |
C0008209 | An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family. | Chlorine|Gas, Chlorine|Cl2 Gas|chlorine|Chlorine (substance)|Chlorine Gas|Cl element|Chlorine-35|chlorine gas|Cl - Chlorine|Cl|Chlorine gas|CHLORINE|Gas, Cl2|Chlorine 35|Chlorine, NOS | chlorine |
C0181222 | null | hose|hoses | Hoses |
C0678624 | null | flotation | flotation |
C0038739 | Chemical groups containing the covalent sulfur bonds -S-. The sulfur atom can be bound to inorganic or organic moieties. | Sulfides|Sulfide (substance)|Sulfide|sulphides|sulfides|sulphide|sulfide | Sulfides |
C0206442 | Inorganic compounds that contain zinc as an integral part of the molecule. | Zinc compounds|Zinc Compounds|Compounds, Zinc | Zinc Compounds, Inorganic |
C0132298 | A family of protein growth factors produced by the nervous system and peripheral target tissues. These proteins are critical for development, growth, regeneration, survival, and differentiation of neurons. | Neurotrophin|neutrophin|neurotrophin|neurotrophic factor|NTF|ntf|Neurotrophic Factor | neurotrophic factor |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.